Prime Medicine, Inc. (PRME)
D
Pipeline Grade
Financial Position (from SEC Filings)
$77.8M
Cash & Equivalents
$42.7M
Quarterly Burn Rate
5 mo
Est. Cash Runway
$683M
Market Cap
Estimated from most recent SEC quarterly filing. View SEC filings
Drug Pipeline (0 Assets)
No drugs indexed yet. Pipeline data is populated from ClinicalTrials.gov and openFDA.
Upcoming Catalysts
No upcoming catalysts detected for this company.
Active Clinical Trials (2)
| NCT # | Title | Phase | Status | Enrollment |
|---|---|---|---|---|
| NCT07226622 | Prescreening Study to Identify Potential Wilson Disease Participants for Gene-Editing Clinical Trial | OTHER | Active Not Recruiting | 30 |
| NCT06559176 | A Study of the Safety and Efficacy of Prime Editing (PM359) in Participants With p47phox Autosomal Recessive Chronic Gra... | PHASE2 | Enrolling By Invitation | 12 |
Source: ClinicalTrials.gov. Trial status last updated by sponsor — may not reflect current state.